

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.
百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

CHANGE OF CO-CHAIR OF SCIENTIFIC ADVISORY COMMITTEE

The board of directors (the “**Board**”) of BeiGene, Ltd. (the “**Company**”) hereby announces that effective November 20, 2022, Dr. Alessandro Riva has been appointed as Co-Chair of the scientific advisory committee (the “**Scientific Advisory Committee**”) of the Board. Dr. Corazon (Corsee) D. Sanders ceased to serve as Co-Chair of the Scientific Advisory Committee but remains a member of the Scientific Advisory Committee.

The Scientific Advisory Committee consists of seven members, namely Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Dr. Xiaodong Wang and Mr. Qingqing Yi, with Dr. Xiaodong Wang and Dr. Alessandro Riva serving as Co-Chairs.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, November 21, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi as Independent Non-executive Directors.